The new agreement will provide Lonza with access to Arbor's gene editing technology
Quote from David Cheng, CEO of Arbor:
“Arbor’s differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
Basel, Switzerland and Cambridge, USA, 23 December 2020 – Arbor Biotechnologies and Lonza announced today a license agreement to provide Lonza with access to Arbor’s next generation CRISPR-based gene editing technology. Lonza will have the ability to utilize Arbor’s proprietary technology in its bioproduction products and services. The financial details of this agreement were not disclosed.